Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Open-label, Parallel-controlled Phase III Study Comparing the Efficacy and Safety of HRS9531 Injection Versus Semaglutide Injection in Subjects With Obesity

NCT07285902 is registered in ClinicalTrials.gov with Fujian Shengdi Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT07285902
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07285902 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Open-label, Parallel-controlled Phase III Study Comparing the Efficacy and Safety of HRS9531 Injection Versus Semaglutide Injection in Subjects With Obesity
Lead sponsor
Fujian Shengdi Pharmaceutical Co., Ltd.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
December 25, 2025
Completion date
March 31, 2027
Enrollment
572 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

obesity